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AbstrACt
Objectives to identify genetic determinants of 
susceptibility to clinical vertebral fractures, which is an 
important complication of osteoporosis.
Methods Here we conduct a genome-wide 
association study in 1553 postmenopausal women 
with clinical vertebral fractures and 4340 controls, 
with a two-stage replication involving 1028 cases 
and 3762 controls. potentially causal variants 
were identified using expression quantitative trait 
loci (eQtL) data from transiliac bone biopsies and 
bioinformatic studies.
results A locus tagged by rs10190845 was 
identified on chromosome 2q13, which was 
significantly associated with clinical vertebral 
fracture (p=1.04×10−9) with a large effect size 
(or 1.74, 95% CI 1.06 to 2.6). Bioinformatic 
analysis of this locus identified several potentially 
functional Snps that are associated with expression 
of the positional candidate genes TTL (tubulin 
tyrosine ligase) and SLC20A1 (solute carrier family 
20 member 1). three other suggestive loci were 
identified on chromosomes 1p31, 11q12 and 15q11. 
All these loci were novel and had not previously 
been associated with bone mineral density or clinical 
fractures.
Conclusion We have identified a novel genetic 
variant that is associated with clinical vertebral 
fractures by mechanisms that are independent 
of BMd. Further studies are now in progress to 
validate this association and evaluate the underlying 
mechanism.
IntrOduCtIOn
Osteoporosis is a common disease with a strong 
genetic component. It is characterised by low bone 
mineral density (BMD), deterioration in the micro-
structural architecture of bone and an increased 
risk of fragility fractures. Vertebral fractures are an 
important complication of osteoporosis.1 They are 
characterised by loss of height and deformity of the 
affected vertebrae and associated with increased 
risk of other fractures.2 It has been estimated that 
between 8% and 30% of patients with radiological 
evidence of vertebral fractures (so-called morpho-
metric fractures) come to medical attention for 
reasons that are incompletely understood.3 4 In 
contrast, patients with vertebral fractures that come 
to medical attention because of symptoms such as 
back pain, kyphosis and height loss and are defined 
as having clinical vertebral fractures.5–7 Clinical 
vertebral fractures are associated with a markedly 
increased risk of future fractures and increased 
mortality.8 Major advances have been made in 
identifying genetic variants that regulate BMD, 
and some variants have also been identified that 
predispose to non-vertebral fractures.9–20 However, 
the genetic determinants of vertebral fractures 
are poorly understood. A previous genome-wide 
association study (GWAS) published by Oei and 
colleagues21 involving a discovery cohort of 8717 
cases and 21 793 controls failed to identify any 
significant genetic predictors of radiographic verte-
bral fracture at a genome-wide significant level. 
However, in this study, the vertebral fractures were 
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defined simply on the basis of morphometric analysis of spinal 
radiographs. It is well recognised, however, that the morpho-
metric techniques employed in this study may have identified 
vertebral deformities that were not fractures.22 The aim of the 
present study was to re-evaluate the predictors of clinical verte-
bral fractures by GWAS to try and gain new insights into this 
important and poorly understood clinical problem.
PAtIents And MetHOds
The study involved a discovery phase with 1553 clinical vertebral 
fracture cases and 4340 controls, a first replication phase of 694 
cases and 2105 controls, and a second replication phase of 334 
cases and 1657 controls, as summarised in online supplementary 
table 1. The GWAS was performed using standard methodology 
as detailed in the online supplementary text 1.
results
Characteristics of the study populations
The mean (±SD) age of the patients with clinical vertebral frac-
tures was 71.3±9.3 years with a BMD T-score at the lumbar 
spine of −2.72±1.4 and at the femoral neck of −2.57±1.1. 
The controls were not matched with the cases by age and did 
not undergo phenotyping for vertebral fracture on the basis that 
clinical vertebral fractures are uncommon in the general popula-
tion (estimated incidence of 9.8/1000 person-years in individuals 
aged 75–84 years).23 While it is possible that clinical vertebral 
fractures may have occurred in some controls in later life, this is 
unlikely to have substantially affected the results of the analysis, 
other than to have potentially slightly reduced its power.24 This 
approach has been used previously for genome-wide studies in 
various common diseases including diabetes, Paget’s disease and 
rheumatoid arthritis.25 26
We identified 334 clinical vertebral fracture female cases from 
the UK Biobank cohort with a mean age (±SD) of 58.8±7.7 
years, and they were age-matched with 1657 female controls 
from the same cohort.
Genome-wide association analysis of the discovery sample
Since different genotyping platforms were used in the analysis 
of the different cohorts that constitute the discovery sample, 
association analysis was conducted following imputation of all 
genotypes into the CEU (Utah Residents (CEPH) with Northern 
and Western European ancestry) panel of HapMap II reference 
(see Patients and Methods section). Following imputation, we 
analysed 2 366 456 SNPs and identified 31 with suggestive 
evidence of association with vertebral fracture (P≤10−4). Details 
are summarised in online supplementary table 2; the Manhattan 
and quantile–quantile plots are shown in online supplementary 
figures 2 and 3. Each study was corrected by genomic control; 
genomic inflation factors ranged between λ=1.001–1.046 for 
genotyped SNPs and λ=1.006–1.036 after imputation.
replication and combined analysis
We analysed the 31 suggestively associated SNPs identified in the 
discovery cohort (online supplementary table 4) and seven addi-
tional SNPs that had been significantly associated with clinical 
fractures in a previous GWAS (online supplementary table 5) in 
the replication sample.10 Four SNPs showed nominal association 
(P<0.05) with clinical vertebral fractures at replication (table 1). 
The combined discovery and replication analysis corrected for 
age identified one SNP (rs10190845) on chromosome 2q13 
with genome-wide significant evidence of association with 
clinical vertebral fractures (P=1.27×10−8). The predisposing t
ab
le
 1
 
Va
ria
nt
s 
sh
ow
in
g 
su
gg
es
tiv
e 
or
 s
ig
ni
fic
an
t a
ss
oc
ia
tio
n 
w
ith
 v
er
te
br
al
 fr
ac
tu
re
Ch
r
sn
P
Po
si
ti
on
d
is
co
ve
ry
(n
=
58
93
)
re
pl
ic
at
io
n
(n
=
27
99
)
Co
m
bi
ne
d*
(n
=
86
92
)
u
K 
bi
ob
an
k 
re
pl
ic
at
io
n
(n
=
19
91
)
to
ta
l†
(n
=
10
 6
83
)
A
A
F
P
O
r 
(9
5%
 C
I)
A
F
P
O
r 
(9
5%
 C
I)
P
O
r 
(9
5%
 C
I)
I2
Q
 P
 v
al
ue
s
A
F
P
O
r 
(9
5%
 C
I)
P
O
r 
(9
5%
 C
I)
I2
Q
 P
 v
al
ue
2
rs
10
19
08
45
11
21
92
94
4
A
0.
03
2.
4×
10
–5
1.
70
 (1
.3
3 
to
 2
.1
7)
0.
05
1.
60
×
10
–4
1.
84
 (1
.3
4 
to
 2
.5
3)
1.
27
×
10
–8
1.
75
 (1
.4
5 
to
 2
.1
2)
5.
9
0.
39
0.
05
0.
02
7
1.
66
 (1
.0
6 
to
 2
.6
0)
1.
04
×
10
–9
1.
75
 (1
.4
5 
to
 2
.1
2)
0.
0
0.
48
11
rs
71
21
75
6
57
98
04
25
A
0.
29
5.
2×
10
–5
1.
22
 (1
.1
1 
to
 1
.3
5)
0.
28
0.
01
1
1.
23
 (1
.0
5 
to
 1
.4
5)
1.
27
×
10
–6
1.
23
 (1
.1
3 
to
 1
.3
3)
0.
0
0.
67
0.
29
0.
35
1.
09
 (0
.9
1 
to
 1
.3
2)
4.
39
×
10
–7
1.
22
 (1
.1
3 
to
 1
.3
2)
49
.0
0.
03
15
rs
22
90
49
2
92
46
47
44
A
0.
23
3.
4×
10
–5
1.
24
 (1
.1
2 
to
 1
.3
7)
0.
21
0.
02
1
1.
23
 (1
.0
3 
to
 1
.4
6)
1.
61
×
10
–6
1.
24
 (1
.1
3 
to
 1
.3
5)
53
.7
0.
02
0.
22
0.
44
1.
08
 (0
.8
8 
to
 1
.3
3)
2.
51
×
10
–7
1.
23
 (1
.1
3 
to
 1
.3
3)
75
.6
1.
1×
10
–5
1
rs
13
60
18
1
68
24
84
52
C
0.
16
8.
4×
10
–5
1.
25
 (1
.1
2 
to
 1
.4
1)
0.
17
0.
00
8
1.
30
 (1
.0
7 
to
 1
.5
6)
1.
87
×
10
–6
1.
26
 (1
.1
4 
to
 1
.4
1)
7.
7
0.
57
0.
17
0.
38
0.
90
 (0
.7
2 
to
 1
.1
4)
1.
09
×
10
–5
1.
22
 (1
.1
2 
to
 1
.3
3)
32
.2
0.
57
Th
e 
al
le
le
 (A
) a
nd
 a
lle
le
 fr
eq
ue
nc
y 
(A
F)
 fo
r e
ac
h 
of
 th
e 
va
ria
nt
s 
is
 s
ho
w
n 
al
on
g 
w
ith
 th
e 
P 
va
lu
e 
fo
r a
ss
oc
ia
tio
n,
 O
R 
an
d 
95
%
 C
I. 
Q
 P
 v
al
ue
s 
co
rr
es
po
nd
 to
 C
oc
hr
an
’s 
Q
 P
 v
al
ue
s. 
Th
e 
va
lu
es
 s
ho
w
n 
ar
e 
ad
ju
st
ed
 fo
r a
ge
, b
ut
 s
im
ila
r r
es
ul
ts
 w
er
e 
ob
ta
in
ed
 fo
r u
na
dj
us
te
d 
as
so
ci
at
io
n 
te
st
s. 
Po
si
tio
n 
re
fe
rs
 to
 H
um
an
 G
en
om
e 
As
se
m
bl
y 
G
RC
h3
8.
p1
1.
*C
om
bi
ne
d 
re
su
lts
 s
ho
w
ed
 th
e 
m
et
a-
an
al
ys
is
 fo
r d
is
co
ve
ry
 a
nd
 re
pl
ic
at
io
n 
st
ag
e.
†T
ot
al
 re
su
lts
 s
ho
w
ed
 th
e 
m
et
a-
an
al
ys
is
 in
cl
ud
in
g 
th
e 
se
co
nd
 re
pl
ic
at
io
n 
in
 th
e 
U
K 
Bi
ob
an
k 
co
ho
rt
.
group.bmj.com on December 19, 2017 - Published by http://ard.bmj.com/Downloaded from 
3Alonso N, et al. Ann Rheum Dis 2017;0:1–8. doi:10.1136/annrheumdis-2017-212469
Clinical and epidemiological research
allele had a frequency of 0.034 in cases compared with 0.022 
in controls and the OR for susceptibility to fracture was 1.75 
(95% CI 1.44 to 2.12) (figure 1). The results were similar 
without age correction (P=4.9×10−8; OR 1.66 (95% CI 1.38 to 
1.99)). Conditional analysis on rs10190845 did not reveal any 
secondary association signals at the locus (online supplementary 
figure 4). Three other SNPs on chromosomes 1p31, 11q12 and 
15q11 were suggestively associated with vertebral fracture in the 
combined analysis (table 1 and online supplementary figures 5 
and 6). None of these regions have been found to be associated 
with BMD or fracture in previous GWAS.10 13
The top SNP (rs10190845) maps to a region that contains 11 
potential candidate genes (figure 2). This region has previously 
been implicated as a genetic regulator of bone density by Estrada 
and colleagues,10 who reported that rs17040773 within ANAPC1 
(anaphase promoting complex subunit 1) was associated with 
femoral neck BMD (P=1.5×10−9), but not with clinical frac-
tures (P=0.79). rs17040773 is not in linkage disequilibrium with 
rs10190845 in our population (r2=0.006), and in keeping with 
this, when we performed conditional analysis on rs17040773, 
we confirmed that rs10190845 remained significantly associated 
with clinical vertebral fractures (P=2.09×10−8; OR 1.73 (95% 
CI 1.43 to 2.09)). In order to test whether the variants associ-
ated with clinical vertebral fractures played a role in BMD, we 
tested the rs10190845 variant for association with volumetric 
vertebral BMD in females on the dataset from Nielson and 
colleagues.27 We did not find any association for the variant and 
BMD (P=0.23). This suggests that rs10190845 constitutes an 
independent signal that predisposes to clinical vertebral fracture 
by mechanisms that are independent of an effect on BMD.
A second replication for the significant hit on chromosome 
2 and suggestive SNPs on chromosomes 1, 11 and 15 was 
performed in 334 clinical vertebral fracture cases and 1657 
controls from UK Biobank. The top hit (rs10190845) on chro-
mosome 2 was found nominally associated with clinical verte-
bral fractures (P=0.027, OR=1.66 (95% CI 1.06 to 2.60), 
minor allele frequency (MAF)=0.049). No association was 
found for the suggestive SNPs in this cohort (table 1).
Meta-analysis of the discovery and the two replication stages 
showed a combined p-value for rs10190845=1.04×10-9 
(OR=1.74 (95% CI 1.06–2.6)) with no evidence of heteroge-
neity between cohorts (I2=0.0, P=0.48) (table 1).
The SNPs rs7121756 on chromosome 11 and rs2290492 
on chromosome 15 showed significant heterogeneity among 
cohorts (Cochrane’s Q<0.05), and a random effect analysis was 
performed. rs7121756 remained suggestively associated with 
clinical vertebral fractures (P=1.01×10−6), while rs2290492 
showed a marginal association (P=0.004).
Functional evaluation of chromosome 2q13 locus
This analysis focused on a linkage disequilibrium block of 
approximately 700 kb surrounding the top hit rs10190845. 
We identified a total of 936 SNPs within the region that were 
analysed in the GWAS (n=376) or that were in linkage disequi-
librium (r2 value of >0.7) with rs10190845 or that showed 
suggestive association to clinical vertebral fractures (P<5×10−3). 
We imputed the genotypes for the SNPs within the region of 
interest using the 1000 Genomes phase 3 panel as reference and 
tested the SNPs for association with clinical vertebral fractures. 
We removed 878 of the SNPs since they showed no association 
with clinical vertebral fractures in our dataset (P>0.05). The 
remaining 58 candidate SNPs were tested for association with 
the level of expression of genes within the candidate locus using 
a bone-derived gene expression dataset (eQTLs)28 (tables 2 and 
3 and online supplementary figure 7). This resulted in the iden-
tification of nine SNPs that were eQTLs for genes within the 
region. In order to gain insight into the functional basis of the 
association at 2q13, we used SuRFR,29 which integrates func-
tional annotation and prior biological knowledge to identify 
potentially causal genetic variants to assess these nine SNPs 
along with the top hit rs10190845 (table 2 and online supple-
mentary figure 7).
The top ranking variant identified by SuRFR, rs35586251, 
located within exon 3 of FBLN7, is a non-synonymous substi-
tution (p.Val119Met). However, analysis using various in silico 
software tools yielded inconsistent results with regard to func-
tionality of this SNP at the protein level (online supplementary 
table 6). The other nine SNPs are associated with expression of 
TTL, SCL20A or both genes. The variant that ranked top by 
SuRFR, rs35586251, was associated with increased expression 
of TTL (P=6.6×10−6). Four other variants were also associated 
with both increased expression of TTL and reduced expression 
Figure 1 Cohort specific association between rs10190845 and clinical 
vertebral fracture. The point estimates (squares) and 95% CIs (horizontal 
lines) for individual studies are shown with the summary indicated by 
the diamond using a fixed effect model. Summaries are shown for meta-
analysis with discovery cohorts only (Summary_discovery), with the first 
replication cohorts only (Summary_replication), and for the whole three-
stage meta-analysis (Summary_meta-analysis). ‘BRITISH-WTCCC’ shows 
the results for the combined cohorts CAIFOS, AOGC, DOES and EPIC and 
the control cohort WTCCC2. ‘Scottish replication’ corresponds to EDOS-
ORCADES cohorts, ‘Italian_replication_1’ study corresponds to Florence-
InCHIANTI cohorts and ‘Italian_replication_2’ study comprises the Turin 
and Siena cohorts. Cohort sizes are reflected by square dimensions.
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of SLC20A1 (P values ranging from 2.1×10–6 to 10−5). The 
second ranking variant, rs77172864, in strong linkage disequi-
librium (LD) with the GWAS top hit (r2=0.79), was associated 
with reduced expression of SLC20A1 (P=10−4) (tables 2 and 3).
The variants listed on table 2 were tested in the UK Biobank 
cohort for further association with clinical vertebral fractures 
(online supplementary table 7). Although none of them was 
significantly associated with the trait, a trend of significance was 
found for SNPs rs72943913, rs77172864 and rs113428223 
(P=0.06, OR=1.66), and all of them were identified as eQTLs 
for SLC20A1 gene in bone. These variants showed a lower 
frequency (MAF=0.03) than the top hit (MAF=0.05), which 
could require a greater sample size to detect associations with 
the trait.
Association between clinical vertebral fractures and other 
osteoporosis-related phenotypes
In order to determine if there is overlap between the SNPs iden-
tified as associated with lumbar spine BMD in previous GWAS 
with those associated with clinical vertebral fracture in this study, 
we evaluated 50 SNPs that have been associated with lumbar 
spine BMD at a genome-wide significant level in previous studies 
in our dataset.10 11 13 30 31 Four variants were nominally associ-
ated with clinical vertebral fracture after Bonferroni correction 
(table 4). We also analysed 15 variants previously associated with 
clinical fracture,13 of which three were associated with clinical 
vertebral fractures in this study. We also analysed the SNPs iden-
tified by Nielson and colleagues27 as genome-wide significant 
predictors of volumetric vertebral BMD for association with 
clinical vertebral fractures in our dataset. Of the six genome-
wide significant SNPs identified by Nielson et al, we found that 
one was significantly associated with clinical vertebral fractures 
after Bonferroni correction (rs12742784, P=6.24×10−5). The 
BMD-increasing variants in table 4 conferred a reduced risk of 
clinical vertebral fractures in our study, while the variants asso-
ciated with appearance of clinical fractures in previous studies 
were also associated with a higher risk of developing a clinical 
vertebral fracture in our data.
dIsCussIOn
Many advances have been made in defining the genetic determi-
nants of BMD and fractures through large-scale GWAS, genome 
sequencing studies and linkage studies in rare bone diseases.32 
For example, linkage studies have shown that loss-of-function 
and gain-of-function variants in LRP5 cause early onset osteopo-
rosis33 and high bone mass,34 respectively, whereas loss of func-
tion mutations affecting SOST and LRP4 have been identified 
as causes of high bone mass and osteosclerosis.35 36 GWAS and 
genome sequencing studies have also been successful in iden-
tifying multiple loci that regulate BMD9–11 30 37 and a smaller 
number that predispose to clinical fractures.10 30
Although vertebral fractures are one of the most common 
and important complications of osteoporosis, relatively little is 
known about the genetic determinants of this type of fracture.38 
In a previous study of 8717 cases and 21 793 controls, Oei and 
colleagues failed to identify any locus with significant evidence 
of association with morphometric vertebral fractures.21 In the 
present study, however, we were successful in identifying one 
genome-wide significant variant that predisposed to clinical 
vertebral fractures, which was replicated in several populations. 
We also detected loci that might play a role in clinical vertebral 
fractures (showing suggestive association at the genome-wide 
Figure 2 Regional association plots of susceptibility locus for clinical vertebral fracture. The figure shows the results after imputation using 1000G 
v3 as reference panel. The SNPs are colour coded according to the extent of linkage disequilibrium with the SNP showing the highest association 
signal from the combined analysis (represented as a purple diamond). The estimated recombination rates (cM/Mb) from HapMap CEU release 22 are 
shown as light blue lines, and the blue arrows represent known genes in the region. The red line shows the threshold for genome-wide significance 
(P=5×10−8).
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level), but further studies need to be performed in further 
cohorts to confirm or refute these associations. A likely reason 
for the difference between our findings and those of Oei et al is 
varying case definition. Here, we studied patients with clinical 
vertebral fractures as opposed to morphometric vertebral defor-
mities, many of which may not be true fractures.22 The genome-
wide significant SNP identified in the present study, rs10190845, 
shows one of the largest effect sizes so far detected in the field of 
osteoporosis genetics (OR=1.75 (95% 1.45 to 2.12)). Most of 
the signals associated with BMD or fracture to date showed a very 
low effect (ORs between 0.90 and 1.10),12 13 with a few excep-
tions.20 rs10190845 maps to chromosome 2q13, a region previ-
ously associated with low femoral neck bone density.10 However, 
when conditioning on rs17040773, the previously reported top 
SNP at the locus,10 the association with rs10190845 remained 
significant, indicating that rs10190845 represents a novel signal.
In order to determine if there was an overlap between the 
results of this study and those previously reported, we analysed 
71 SNPs that have previously been associated with either spine 
BMD or clinical fractures and identified seven variants that were 
significantly associated with clinical vertebral fracture in this 
study, after Bonferroni correction (threshold for significance 
0.0009 for BMD and 0.003 for clinical fractures). However, the 
association for these variants did not reach genome-wide signif-
icance; therefore, they were not selected in the GWAS analysis. 
The SNPs associated with low BMD as well as increased risk 
of clinical fractures in previous studies were associated with an 
increased risk of clinical vertebral fractures in this study and 
those associated with an increased risk of clinical fractures in 
previous studies were associated with an increased risk of clinical 
vertebral fractures in this study.
Furthermore, when we analysed six SNPs that were signifi-
cantly associated with vertebral BMD on quantitative CT anal-
ysis,27 one locus on chromosome 1p36, close to ZBTB40, was 
identified and significantly associated with clinical vertebral 
fracture in this study. These results support the importance of 
ZBTB40 as a predictor of clinical fractures and suggest that the 
mechanism of association is most probably mediated by changes 
in BMD. The observations in this study, when taken together 
with the findings of Nielson and Estrada,10 27 indicate that there 
is a partial overlap between loci that regulate lumbar spine BMD 
and clinical vertebral fractures. However, there are some genetic 
determinants of clinical vertebral fracture that are unique and 
that operate independently of BMD.
In order to identify the mechanisms by which 2q13 predis-
poses to vertebral fracture, we conducted bioinformatic analyses 
to determine if rs10190845 or other SNPs nearby were likely 
to be functional variants. These studies identified several poten-
tially functional SNPs in the same LD block as rs10190845, 
which might account for the association we observed. The top 
ranking SNP from SuRFR analysis was rs35586251, which was 
strongly associated with expression of the TTL gene within the 
candidate locus (online supplementary figure 8). However, the 
second ranking SNP, rs77172864 (online supplementary figure 
9), in strong LD with the GWAS top hit, was significantly asso-
ciated with the expression of SLC20A1. Several other SNPs 
were also significantly associated with expression of TTL and/
or SLC20A1, raising the possibility that alterations in expression 
of one or both genes might account for the predisposition to 
clinical vertebral fractures. Association analysis performed using 
UK Biobank cohort for these SNPs showed a trend of associa-
tion for markers regulating SLC20A1 gene, which also showed 
some degree of linkage disequilibrium, with the GWAS top hit. 
The lack of significant association might be due to their low t
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allele frequency (MAF=0.03), which means that a larger sample 
size may be required to detect a strong association. The tubulin 
tyrosine ligase encoded by TTL is involved in regulation of the 
cytoskeleton. Previous studies have shown that TTL is involved 
in neuronal development39 and injury signalling,40 raising the 
possibility that variants that regulate TTL might be involved in 
regulating pain perception, which could account for the fact that 
predisposing variants have not previously been associated with 
BMD. Other mechanisms are also possible and further studies 
need to be performed in order to address the role of TTL in clin-
ical vertebral fracture. The other main candidate gene, SLC20A1, 
encodes Pit1, which facilitates the entry of inorganic phosphate 
into the cytoplasm.41 Previous studies have shown that SLC20A1 
is involved in mineralisation.42–45 Altered expression of this gene 
could convey risk for vertebral fractures through an effect on 
bone mineralisation. Although SLC20A1 presents as the candi-
date gene for association with clinical vertebral fractures in this 
study, it has not been identified previously as a predictor of BMD 
or fractures. This opens the possibility that alternative mecha-
nisms may be operative for SLC20A1 or that TTL rather than 
SLC20A1 is the candidate gene within the 2q13 locus.
Limitations of the study include the fact that the total sample 
size was relatively small and the power to detect alleles of modest 
effect size was limited. It is possible that we may have missed 
associations between rare variants and clinical vertebral frac-
tures since the imputation we performed was against HapMap 
reference panel rather than larger panels that increase imputa-
tion power particularly against low frequency variants. Although 
the case definition was clinically based, there was no significant 
heterogeneity in the associations we observed across centres.
Strengths of the present study are that it has provided 
important new information on the genetic determinants of clin-
ical vertebral fracture and that results, despite the sample size, 
have been validated in two independent replication stages.
table 3 Correlation between genotypes for potentially functional SNP and bone-specific expression of genes in the candidate region
rank snP Gene Probe A1 A2 FrQ beta se P
1 rs35586251 TTL 224896_s_at A G 0.017 0.65 0.13 6.62×10–6
2 rs77172864 SLC20A1 230494_at G A 0.013 −0.46 0.11 0.00011
4 rs77996972 TTL 224896_s_at T C 0.012 0.67 0.13 3.80×10–6
SLC20A1 230494_at T C 0.012 −0.49 0.11 5.50×10–5
5 rs75814334 TTL 224896_s_at T C 0.013 0.67 0.13 2.10×10–6
SLC20A1 230494_at T C 0.013 −0.48 0.11 6.60×10–5
6 rs74792868 TTL 224896_s_at A G 0.012 0.66 0.14 2.00×10–5
SLC20A1 230494_at A G 0.012 −0.53 0.12 2.80×10–5
6 rs72943913 SLC20A1 230494_at G A 0.013 −0.46 0.11 0.00011
7 rs112275607 TTL 224896_s_at A G 0.013 0.67 0.13 2.80×10–6
SLC20A1 230494_at A G 0.013 −0.48 0.11 6.02×10–5
8 rs113085288 SLC20A1 230494_at T A 0.008 −0.72 0.14 4.06×10–6
9 rs113428223 SLC20A1 230494_at T C 0.013 −0.46 0.11 0.0001
The data shown are only for the associations that were significant after Bonferroni correction (P value for significance ≤0.0002).
Probe IDs obtained from the Affymetrix HG U133 2.0 plus array.
A1, allele 1; A2, allele 2; Beta, effect size on regression analysis referred to A1 allele; FRQ, frequency of allele 1; SE, SE of beta estimate.
Gene names: TTL, tubulin tyrosine ligase; SLC20A1, solute carrier family 20 member 1 (also known as PIT1).
table 4 Association between known genetic determinants of spine BMD and clinical vertebral fractures in the combined GWAS dataset
Previous studies Present study
 study snP locus
Candidate 
gene Phenotype Method Allele beta1 P beta2 P
Estrada rs1346004 2q24.3 GALNT3 LS-BMD DXA A -0.06 3.87×10-30 +0.16 0.0002
Estrada rs4727338 7q21.3 SLC25A13 LS-BMD DXA C +0.07 2.13×10-35 −0.15 0.0004
Estrada rs6426749 1p36.12 ZBTB40 LS-BMD DXA C +0.1 1.86×10-44 −0.22 0.0003
Styrkarsdottir rs7524102 1p36 WNT4 LS-BMD DXA A −0.11 9.2×10–9 +0.23 0.0002
Estrada rs4727338 7q21.3 SLC25A13 Clinical fracture Clinical records and 
X-rays
G +0.08 5.9×10–11 +0.14 0.0004
Estrada rs6426749 1p36.12 ZBTB40 Clinical fracture Clinical records and 
X-rays
G +0.07 3.6×10–6* +0.22 0.0003
Estrada rs6959212 7p14.1 STARD3NL Clinical fracture Clinical records and 
X-rays
T +0.05 7.2×10–5* +0.15 0.001
Nielson rs12742784 1p36.12 ZBTB40 Vertebral BMD qCT imaging T +0.09 1.05×10–10 −0.20 6.24×10–5
The variants shown are those that were significant after Bonferroni correction for testing 56 BMD variants (P threshold for association 0.0009) and 16 fracture variants (P 
threshold for association 0.003).
Beta1 showed the effect for the previous studies (lumbar spine bone mineral density , clinical fracture and vertebral bone mineral density).
Beta2 showed the effect for the present study on clinical vertebral fracture.
Method column shows the technique used to evaluate the BMD or assess the fracture.
*SNP significantly associated with clinical fracture after Bonferroni correction (P threshold at Estrada et al 5×10–4).
Gene names: GALNT3, polypeptide N-acetylgalactosaminyltransferase 3; SLC25A13, solute carrier family 25 member 13; STARD3NL, StAR related lipid transfer domain 
containing 3 N-terminal like; WNT4, Wnt family member 4; ZBTB40, zinc finger and BTB domain containing 40.
BMD, bone mineral density; DXA, dual energy X-ray absorptiometry; qCT, quantitative CT.
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COnClusIOn
Genome wide association analysis identified a significant asso-
ciation between a marker on chromosome 2 and clinical verte-
bral fractures in postmenopausal women, a finding validated in 
several independent populations.
It is of interest that the top hit and other suggestive hits iden-
tified acted independently of BMD, bringing to attention other 
bone microarchitectural modalities that determine fracture 
susceptibility. This suggests that the variants identified might be 
acting as markers for perception of pain or other factors that are 
associated with the clinical presentation of vertebral fractures. 
We also found that some of the variants previously identified as 
regulators of spine BMD were associated with clinical vertebral 
fractures but with effects that were weaker than the top hit and 
other suggestive hits. Taken together, the data suggest that the 
genetic basis of clinical vertebral fracture is complex involving 
variants that act independently of BMD as well as those that are 
associated with spine BMD. Further research is now warranted 
to fully investigate the mechanisms involved.
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